Harvia Plc, Half-year financial review 7 August 2025 at 9:00 a.m. EEST Harvia Q2 2025: Continued sales growth in uncertain market conditions This release is a summary of Harvia Plc’s Half-year financial review January–June 2025. The complete report is attached to this release as a pdf file. It is also available on Harvia’s website at https://harviagroup.com/. Highlights of the review period April–June 2025: Revenue increased by 9.4% to EUR 47.3 million (43.2). At comparable exchange rates, revenue increase ...

Financial Data and Key Metrics Changes - Orion reported Q1 2026 revenue of $19.6 million, a slight decrease from $19.9 million in Q1 2025, with two of the three segments showing year-over-year growth [19] - The gross profit percentage rose to over 30% for the first time in six years, with a net loss reduced to $1.2 million from $3.6 million in Q1 2025 [11][17] - Adjusted EBITDA improved to positive $200,000 in Q1 2026 compared to a negative $1.8 million in Q1 2025 [22] Business Line Data and Key Metrics Changes - LED lighting segment revenue increased by 1% to $12.9 million, while the electrical maintenance segment revenue rose by 21% to $4 million [19][20] - EV charging solutions revenue decreased to $2.7 million from $3.8 million, primarily due to the timing of larger projects [20] - The gross margin for the LED lighting segment improved to 31.8% from 22.6%, and the maintenance segment gross margin increased to 22.4% from 3.8% [20] Market Data and Key Metrics Changes - The company is experiencing tailwinds in all three business lines nationally and regionally, with a focus on converting quality leadership into market leadership [8] - The electrical infrastructure market is seeing significant investments, providing a unique opportunity for Orion to leverage its expertise [15] Company Strategy and Development Direction - The company aims to achieve $84 million in revenue for FY 2026, with a growth expectation of 5% [24] - Orion is focusing on enhancing margins, reducing costs, and expanding its footprint in existing maintenance service customers [12][13] - The decision was made to retain the existing operational structure rather than reorganizing into two business units, allowing for better integration of EV solutions [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving year-over-year growth in revenue, profitability, and shareholder value [6] - The company anticipates modest growth in LED lighting and electrical maintenance revenues, with flat to slightly lower EV charging revenues due to funding uncertainties [25] - Management believes that the company is well-positioned to manage tariff impacts due to its domestic manufacturing capabilities [25] Other Important Information - Orion has made significant reductions in overhead and has built a diversified pipeline of revenue to support growth [17] - The company has reduced total operating expenses by 10.6% to $6.9 million in Q1 2026 from $7.7 million in Q1 2025 [12][22] Q&A Session Summary Question: Interest in electrical infrastructure and potential investment needed - Management indicated that they are in the early stages of electrical infrastructure development and believe their current infrastructure can manage growth without significant initial investment [32] Question: Expectations for pipeline impact in fiscal 2027 and beyond - Management confirmed that the current pipeline will contribute to revenue growth in fiscal 2027 and beyond [35] Question: Details on the electrical infrastructure project - Management stated that the initial project involves expanding electrical infrastructure work based on customer requests, with more details to be shared in future releases [39][40] Question: Clarification on the Boston Public Schools contract - Management clarified that the recent $6.5 million contract is an expansion of previous work done for the Boston Public Schools, indicating a significant increase in project scope [43][46] Question: Status of fluorescent bulb ban and its impact - Management acknowledged the potential impact of the fluorescent bulb ban on business but indicated that it is too early to assess enforcement [50][52]

Key Takeaways One-Month Price Return Performance Image Source: Zacks Investment Research This underperformance raises the question: Should investors cut their losses and exit, or is it worth holding CRWD stock? CrowdStrike's Premium Valuation: A Key Concern CRWD's lofty valuation make it vulnerable to further correction. CrowdStrike is currently trading at a high price-to-sales (P/S) multiple, far above the Zacks Security industry. CrowdStrike's forward 12-month P/S ratio sits at 21.38X, significantly highe ...

Core Viewpoint - Roku's shares have significantly declined despite solid Q2 earnings that exceeded analyst expectations, now trading at levels similar to August 2022, and have halved over the past five years [1] Group 1: Financial Performance - Roku reported Q2 revenue of $1.1 billion, a 15% year-over-year increase, surpassing the $1 billion analyst consensus [7] - The company achieved an EPS of $0.07, significantly better than the expected loss of $0.15, primarily due to net operating income [7] - Platform revenue grew 15% to $975.5 million, while device revenue fell 6% to $135.6 million, with video advertising driving growth [8] - Adjusted EBITDA surged 79% year-over-year to $78.2 million, exceeding the guidance of $70 million [9] - For Q3, Roku projects revenue of $1.2 billion, a 13% year-over-year increase, with adjusted EBITDA of $110 million and net income of $10 million [11] Group 2: Business Strategy - Roku's primary business focus is its platform, which generates revenue through subscription cuts and advertising, similar to the Apple App Store [2] - The company aims to improve profitability by growing platform revenue, utilizing its home screen for recommendations and bundles to drive subscriptions [5] - Roku is integrating its acquisition of Frndly TV, which offers budget-friendly live TV channels, to enhance ad sales and partnerships with Demand-Side Platforms [6] Group 3: Future Outlook - Roku forecasts 2025 revenue to reach approximately $4.65 billion, with an increased platform revenue forecast of $4.075 billion, representing a 16% growth [10] - The company expects to become operating income positive in Q4, earlier than previously anticipated, and aims for further EBITDA margin improvements next year [4] - Investors are encouraged to consider buying the dip, as Roku continues to show strong revenue growth and is moving towards profitability [13][14]

Core Viewpoint - Graham reported a significant improvement in profitability for Q1 FY2026, with non-GAAP EPS of $0.45 exceeding analyst estimates, but GAAP revenue fell short of expectations at $55.5 million [1][2]. Financial Performance - Non-GAAP EPS increased by 36% year-over-year, from $0.33 in Q1 FY2025 to $0.45 in Q1 FY2026 [2][6]. - GAAP revenue was $55.5 million, which was below the expected $63.4 million, despite an 11% year-over-year increase [2][5]. - Gross margin improved to 26.5%, up 1.7 percentage points from the previous year, while operating margin rose to 8.9% compared to 6.5% in Q1 FY2025 [2][5]. - Adjusted EBITDA climbed 33% to $6.8 million [2][6]. Orders and Backlog - The total order figure reached $125.9 million, more than doubling compared to the same quarter last year, resulting in a record book-to-bill ratio of 2.3x [7][11]. - Backlog increased by 22% year-over-year to $482.9 million, with approximately 87% tied to Defense projects [7][11]. Business Strategy - Graham focuses on expanding into new markets, innovation, and deepening ties to U.S. defense programs while maintaining financial discipline [4][3]. - The integration of P3 Technologies has enhanced capabilities in turbomachinery, allowing for novel project pursuits [12]. Future Guidance - The company maintains its FY2026 guidance, projecting net sales between $225 million and $235 million and adjusted EBITDA of $22 million to $28 million [14]. - Capital expenditures for FY2026 are planned between $15 million and $18 million, targeting 8-10% annual organic revenue growth [14].

Financial Data and Key Metrics Changes - Global net revenue for Q2 2025 was $69.4 million, a 4% increase compared to 2024, driven by the successful launch of Evolisse and international revenue growth [28] - Reported gross margin for Q2 was 65.3%, with adjusted gross margin at 66.5%, impacted by a higher mix of international sales and introductory pricing for Evolisse [28][29] - GAAP operating expenses for Q2 were $55.5 million, down from $61.8 million in Q1, while non-GAAP operating expenses were $54 million compared to $52.9 million in Q1 [30][31] - Non-GAAP operating loss in Q2 was $7.9 million, compared to non-GAAP operating income of $1.1 million in 2024 [31] Business Line Data and Key Metrics Changes - Jeuveau experienced its first year-over-year decrease since launch, reflecting a decline in consumer sentiment and procedural volumes in the U.S. aesthetic toxin market [6][8] - Evolisse generated $9.7 million in revenue in its first quarter, marking the strongest first-quarter filler launch in over a decade [18] - The company maintained a 14% market share in the toxin market through the first half of the year, an increase from 13% in 2024 [15] Market Data and Key Metrics Changes - Procedural volumes in the U.S. toxin category have decreased over the past three consecutive quarters, with a notable impact on Jeuveau demand in Q2 [8][10] - Surveys indicated a potential rebound in patient volume in the second half of the year, with a majority of practices expecting growth of over 10% [9] Company Strategy and Development Direction - The company revised its 2025 revenue guidance to a range of $295 million to $305 million, reflecting 11% to 15% growth over 2024 [11][34] - Evolisse is expected to contribute 10% to 12% of total revenue for 2025, with a focus on maintaining long-term growth and profitability [20][34] - The company aims to achieve $700 million in revenue by 2028, with a non-GAAP operating income margin of 20% [33][34] Management's Comments on Operating Environment and Future Outlook - Management noted that the market environment has been challenging, with a significant slowdown in demand observed in the last two weeks of Q2 [6][10] - Despite the challenges, management expressed confidence in the company's ability to deliver sustainable growth, supported by strong early adoption of Evolisse and ongoing international expansion [21][90] Other Important Information - The company has implemented strategic reductions in operating expenses, resulting in over $25 million in annualized savings, while maintaining investment in customer-facing activities [13][34] - Evolus Rewards program saw record redemptions of over $224,000, with 65% coming from repeat patients, indicating strong brand loyalty [16] Q&A Session Summary Question: What dynamics are being seen regarding reduced demand? - Management indicated that procedural demand declined in the high single digits, with the slowdown not driven by competitive dynamics but rather overall market conditions [36][38] Question: What was the impact of inventory buying on recorded revenue? - Management suggested that the initial revenue from Evolisse included both stocking and pull-through elements, making it difficult to quantify precisely [40] Question: How do you explain the improvement seen in July? - Management noted a significant shift in business in July, correlating with internal and third-party research indicating a potential rebound [41] Question: What are the expectations for toxin demand trends? - Management highlighted that overall procedural volume did slow in the first half of the year, with some competitors experiencing significant declines [51] Question: What promotional activities are planned for Q4? - Management mentioned adjustments to promotional strategies to help practices with pull-through, including collaborations with beauty magazines [54] Question: What is driving the current consumer sentiment? - Management noted that consumers earning $150,000 or less are feeling the pinch from increased prices and tariffs, impacting their spending on aesthetic treatments [67] Question: How does the company plan to achieve its 2028 targets? - Management reiterated confidence in reaching the $700 million target, emphasizing that the revised guidance does not change the long-term outlook [87]

Financial Data and Key Metrics Changes - Total revenues grew 16% in Q2 2025 and 15% year-over-year compared to the same periods in 2024, driven by strong global demand and new patient starts [13][19] - Non-GAAP diluted earnings per share increased to $1.44, reflecting a growth rate more than three times that of revenue growth [18] - Operating cash flow reached $185 million in Q2, a 55% increase compared to the same period in 2024 [18] Business Line Data and Key Metrics Changes - VOXZOGO revenue increased 20% year-over-year to $221 million, supported by global expansion and new patient starts [13][20] - Enzyme Therapies revenue rose 15% year-over-year to $555 million, with Palynziq and Vimizim contributing significantly to growth [15][26] - Rocadian revenue was $9 million in Q2, primarily from the U.S. and Italy [15] Market Data and Key Metrics Changes - The company expects second half VOXZOGO revenue to be higher than the first half, with full-year revenue guidance adjusted to between $900 million and $935 million [14][15] - The company anticipates continued strong growth in the second half of 2025, leading to an increase in full-year guidance for total revenues [11][19] Company Strategy and Development Direction - The company plans to advance BMN 333, a long-acting therapy for achondroplasia, to a registrational Phase 2/3 study in the first half of next year [9][28] - The acquisition of Inozyme broadens the enzyme therapies portfolio, with a focus on BMN 401 for ENPP1 deficiency [10][31] - The company aims to augment its portfolio with strategic business development transactions to diversify growth strategies [11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver strong growth and value creation for stakeholders through the remainder of 2025 and beyond [11][19] - The management highlighted the essential nature of their medicines and strong patient support programs as key factors in maintaining availability for patients [26] Other Important Information - The company expects to account for the Inozyme acquisition as an asset purchase, impacting financial results in 2025 [19] - The company is on track to submit applications for age extension for Palynziq to include adolescents in the U.S. and EU in the second half of this year [30] Q&A Session Summary Question: Clarification on BMN 333 and safety profile - Management confirmed that the agent referred to is Trans Con CNP and stated that no unexpected safety issues have been observed in the healthy volunteer study [36][38] Question: Thoughts on competitive landscape for achondroplasia - Management noted that while early data showed added growth with growth hormone, long-term benefits remain uncertain, and further data is needed to assess the impact of combinations [42][45] Question: Contributions to VOXZOGO guidance - Management explained that the adjustment in guidance is primarily due to shifting large orders and a better understanding of revenue trends as the year progresses [50][52] Question: Update on ITC proceedings - Management expects the initial determination from the ITC on June 8, 2026, with a completion date targeted for October 8, 2026 [56][58] Question: Details on BMN 333 trial design - Management refrained from providing specific details on powering but expressed confidence in the biological hypothesis being tested [58][60] Question: Update on citizen petition with the FDA - Management stated that the FDA is reviewing the citizen petition and no updates are expected until the PDUFA date of November 30 [88][90]

Financial Data and Key Metrics Changes - Worldwide revenue for Q2 2025 was $48.6 million, representing a growth of 21.7% year-over-year [30] - U.S. revenue was $46.4 million, reflecting a growth of 22.8% [31] - Adjusted EBITDA was positive at $1 million, compared to an adjusted EBITDA loss of $2.7 million in the prior year [34] - Net loss narrowed to $6.2 million or $0.14 per diluted share, compared to a net loss of $8.9 million or $0.22 per diluted share in the prior year [34] - Cash and marketable securities increased to $145.5 million, marking the first quarter of cash flow breakeven [35] Business Line Data and Key Metrics Changes - U.S. procedure volume increased by 25%, with double-digit growth across all modalities [10][32] - The physician base grew by 25%, reaching a record of 1,440 U.S. physicians performing procedures [22] - Average territory productivity reached $2.1 million, representing a 23% increase year-over-year [25] Market Data and Key Metrics Changes - International revenue was $2.2 million, impacted by delayed regulatory clearance for iFuse Torque in Europe [32] - The company expects iFuse Torque to boost revenue growth in Europe starting in 2026 [32] Company Strategy and Development Direction - The company aims to expand its platform of solutions targeting challenging procedures, improving surgical outcomes with lower failure rates [6][8] - Focus on innovation, physician engagement, commercial execution, and operational excellence as key priorities [12] - Plans to launch new products targeting outpatient settings and expand into new addressable markets [21][86] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the demand across the portfolio and the effectiveness of their strategy [44] - The company anticipates continued growth driven by strong physician engagement and product adoption [80] - Guidance for full-year revenue was updated to $195 million to $198 million, implying year-over-year growth of approximately 17% to 18% [36] Other Important Information - The company achieved cash flow breakeven ahead of schedule, indicating potential for consistent positive free cash flow [35] - Leadership changes were announced, with Tony Recoupero retiring and Nicholas Kerr promoted to Chief Commercial Officer [27][28] Q&A Session Summary Question: Guidance on top line growth and assumptions for the second half - Management highlighted strong first-half performance and confidence in continued demand, with a sequential decline expected in Q3 due to seasonality [40][46] Question: Gross margin guidance and pricing pressure - Management discussed maintaining gross margin guidance at 78.5% to 79%, embedding assumptions for ASP pressure while acknowledging potential for better-than-expected outcomes [51][56] Question: Growth of interventional doctors using products - Management noted strong growth from interventional doctors and the potential for further engagement with new product launches [60][62] Question: International market contribution and torque rollout in Europe - Management expressed optimism about the torque product's impact in Europe, with expectations for growth in 2026 [95] Question: Capital deployment priorities - Management indicated a focus on continued investment in R&D and commercial initiatives while maintaining a strong cash position [98]

Core Insights - Investors should prioritize companies that demonstrate strong profitability after accounting for all expenses, favoring profitable firms over those with losses [1] - NVIDIA Corporation, Broadcom Inc., and ServiceNow, Inc. are identified as top investment picks for the second half of the year due to their high net income ratios [2] Net Income Ratio - The net income ratio is a critical measure of a company's profitability, indicating the percentage of net income relative to total sales revenues, with a higher ratio suggesting effective revenue generation and expense management [3] Screening Parameters - Additional criteria for identifying potential investment winners include: - Zacks Rank of 3 or lower, allowing only 'Strong Buys', 'Buys', and 'Holds' [4] - Trailing 12-month sales and net income growth exceeding industry averages [4] - Trailing 12-month net income ratio higher than industry benchmarks [5] - A strong buy percentage rating greater than 70% [5] - These parameters narrowed the stock universe from over 7,685 to just 11 candidates [5] Company Highlights - **NVIDIA Corporation (NVDA)**: - Provides solutions for graphics, computing, and networking globally - Achieved a 12-month net profit margin of 51.7% and holds a Zacks Rank of 3 [5][7] - **Broadcom Inc. (AVGO)**: - Develops semiconductor devices and infrastructure software solutions worldwide - Reports a 12-month net profit margin of 22.6% and also holds a Zacks Rank of 3 [6][7] - **ServiceNow, Inc. (NOW)**: - Offers cloud-based solutions for digital workflows across various regions - Has a 12-month net profit margin of 13.8% and maintains a Zacks Rank of 3 [8][7]

Core Viewpoint - Fastly (FSLY) is expected to report its second-quarter 2025 results on August 6, with anticipated revenue growth and a narrower non-GAAP loss compared to the previous year [1][2][9]. Revenue Expectations - FSLY expects revenues in the range of $143 million to $147 million, representing a 10% year-over-year increase at the midpoint [1][9]. - The Zacks Consensus Estimate for revenues is $145.1 million, indicating a 9.6% increase from the same quarter last year [1]. Loss Forecast - The company anticipates a non-GAAP loss between 4 and 8 cents per share, with the consensus mark for loss at 5 cents per share, which is an improvement from the 7 cents loss reported in the previous year [2][9]. Key Growth Drivers - Fastly's content delivery and edge computing platform is expected to benefit from go-to-market transformation efforts and packaging improvements, aiding in deal acquisition and steady revenue growth [3]. - Enterprise demand for advanced digital experiences and security solutions is likely to support top-line growth, with the Security segment benefiting from ongoing portfolio enhancements [4]. Market Dynamics - Adoption of edge computing solutions, particularly for dynamic content and AI-driven workloads, has been a significant catalyst for growth [4]. - Traditional content delivery remains the primary revenue driver, while security and compute offerings are helping to diversify the revenue mix [4]. Challenges - Competitive industry pricing may constrain gross margin expansion, and profitability is closely tied to operating discipline [6]. - Macroeconomic uncertainty and regulatory factors related to specific customer relationships are expected to negatively impact second-quarter results [6]. Earnings Outlook - According to the Zacks model, FSLY has an Earnings ESP of -53.13% and a Zacks Rank of 3, indicating lower odds of an earnings beat [7].